2 min read
What works globally doesn’t always work in Mexico. And in many cases, the gap is not visible until it’s too late—when a dossier that seemed complete begins to generate questions, delays, or unexpected friction.
For organizations expanding into one of LATAM’s most dynamic pharmaceutical markets, this is where assumptions start to break. Because pharmaceutical dossier requirements in Mexico are not defined solely by structure or data completeness, but by how that information aligns with local regulatory interpretation.
At a global level, the International Council for Harmonisation Common Technical Document (CTD) was designed to create consistency. It works. It standardizes submissions, facilitates global development, and reduces duplication.
But consistency does not guarantee equivalence in evaluation. Under the framework of COFEPRIS, dossiers are not only reviewed for what they contain, but for how they are presented, contextualized, and interpreted within local regulatory logic. And that is where the friction begins.
The issue is rarely the absence of data.
More often, it is a matter of misaligned expectations. Requirements linked to Good Manufacturing Practices under NOM-059-SSA1-2015 or labeling specifications under NOM-072-SSA1-2012 are well documented. Yet, the way they are interpreted in practice can differ from how they are addressed in globally developed dossiers.
What seems compliant in one market may feel incomplete in another.
Not incorrect—just not fully aligned. This misalignment does not appear all at once. It accumulates. A clarification request here.
A formatting inconsistency there. A requirement that was technically addressed—but not in the way it was expected. Individually, these signals may seem manageable. Together, they begin to reshape timelines, introduce uncertainty, and turn what was planned as a straightforward submission into a more complex regulatory pathway.
In a market like Mexico, where demand continues to grow and regulatory expectations evolve, these nuances matter. The opportunity is significant. But so is the cost of getting the interpretation wrong.
This is why the idea of “localizing” a dossier often falls short.
Because this is not about adapting content. It is about translating intent. It requires understanding how regulatory authorities read submissions in practice—how they connect data, how they interpret compliance, and how they evaluate consistency across modules. Not just what is written, but how it is understood.
In that sense, readiness is not defined by completeness. It is defined by alignment with evaluation logic. Global science remains the foundation. But in Mexico, it is not enough on its own.
What determines the outcome is how that science is positioned within a regulatory framework that is both structured and interpretative—where administrative rigor and contextual alignment play a defining role. And in a market with this level of strategic relevance, that distinction becomes more than technical. It becomes operational. And ultimately, commercial.
Bridging the gap between global dossiers and local expectations requires more than adaptation—it requires interpretation.
If your organization is preparing to enter Mexico or navigating dossier misalignment, connect with Freyr to build a submission strategy that accounts for how COFEPRIS evaluates in practice—not just what the global framework prescribes.
